Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion type Assertion NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_head.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion description "[We found that inhibitory receptor KIR2DL1 in combination with HLA-C2 ligand confers susceptibility to chronic hepatitis B (CHB), whereas inhibitory receptor KIR2DL3 or KIR2DL3 homozygote in the presence of HLA-C1C1 genotype shows protection against CHB.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion evidence source_evidence_literature NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion SIO_000772 20643584 NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion wasDerivedFrom befree-20150227 NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.
- NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_assertion wasGeneratedBy ECO_0000203 NP1012676.RAJG5oLEfnjJcciiV20vqY4WGrN3tq9t_HJnI5qytvpSM130_provenance.